CATX Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

4.800

Open

4.740

VWAP

4.00

Vol

8.00M

Mkt Cap

295.00M

Low

3.630

Amount

31.00M

EV/EBITDA(TTM)

Total Shares

74.00M

144.00M

EV/OCF(TTM)

P/S(TTM)

289.00

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.

Events Timeline

(ET)

2026-01-12

07:30:00

Perspective Therapeutics Announces Strategic Updates for Next 12-18 Months

2026-01-09 (ET)

2026-01-09

07:20:00

Perspective Therapeutics Updates Interim Results of 212PbVMT-alpha-NET Clinical Trial

2025-11-10 (ET)

2025-11-10

16:26:16

Perspective Therapeutics announces Q3 earnings per share of 35 cents, surpassing consensus estimate of 32 cents.

2025-10-20 (ET)

2025-10-20

14:08:16

Perspective Therapeutics Declines Following Phase 1/2a Trial Update

News

8.5

15:42 PMNewsfilter

Oncolytics Biotech's Breakthroughs in Cancer Treatment

9.0

01-09Globenewswire

Perspective Therapeutics Updates VMT-α-NET Trial Results, 39% Patient Response Rate Achieved

1.0

2025-12-18Globenewswire

Perspective Therapeutics CEO Thijs Spoor to Present at 2026 J.P. Morgan Healthcare Conference

4.0

2025-11-24Benzinga

Truist Securities Initiates Coverage on Perspective Therapeutics with a Buy Rating and Increases Price Target to $12

6.0

2025-11-21Benzinga

UBS Reiterates Buy Rating for Perspective Therapeutics, Adjusts Price Target to $7

1.0

2025-11-20Newsfilter

Perspective Therapeutics to Attend Conferences Scheduled for December

12 Analyst Rating

Wall Street analysts forecast CATX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CATX is 11.82 USD with a low forecast of 4.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

4.00

Averages

11.82

High

18.00

Current: 0.000

Low

4.00

Averages

11.82

High

18.00

H.C. Wainwright

Buy

upgrade

$10 -> $12

AI Analysis

2026-01-30

New

Reason

H.C. Wainwright

Price Target

$10 -> $12

AI Analysis

2026-01-30

New

upgrade

Buy

Reason

H.C. Wainwright raised the firm's price target on Perspective Therapeutics to $12 from $10 and keeps a Buy rating on the shares. The firm says Sanofi's deprioritization of Alphamedix eliminates a competitor for Perspective .

Truist

NULL -> Buy

initiated

$8 -> $12

2025-11-24

Reason

Truist

Price Target

$8 -> $12

2025-11-24

initiated

NULL -> Buy

Reason

Truist assumed coverage of Perspective Therapeutics with a Buy rating with a price target of $12, up from $8. The company is leading the next wave of radiopharmaceutical innovation, combining manufacturing readiness with cutting-edge molecular design to deliver precision oncology at scale, the analyst tells investors in a research note. Perspective's lead program VMT-alpha-NET has a promising interim phase 1/2B profile, and additional programs in melanoma and FAP offer upside, the firm added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CATX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Perspective Therapeutics Inc (CATX.A) is -1.86, compared to its 5-year average forward P/E of -12.14. For a more detailed relative valuation and DCF analysis to assess Perspective Therapeutics Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.14

Current PE

-1.86

Overvalued PE

5.75

Undervalued PE

-30.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.36

Current EV/EBITDA

-0.33

Overvalued EV/EBITDA

7.28

Undervalued EV/EBITDA

-16.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

233.11

Current PS

350.46

Overvalued PS

740.55

Undervalued PS

-274.33

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

best strong buy for today

Intellectia · 86 candidates

Analyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 55Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

CING

Cingulate Inc

43.00M

CATX

Perspective Therapeutics Inc

262.00M

ELVN

Enliven Therapeutics Inc

2.00B

ADTN

ADTRAN Holdings Inc

758.00M

UTI

Universal Technical Institute Inc

2.00B

CNTA

Centessa Pharmaceuticals PLC

4.00B

Whales Holding CATX

Trading Trends

People Also Watch

Frequently Asked Questions

What is Perspective Therapeutics Inc (CATX) stock price today?

The current price of CATX is 3.79 USD — it has decreased -11.03 % in the last trading day.

What is Perspective Therapeutics Inc (CATX)'s business?

What is the price predicton of CATX Stock?

Wall Street analysts forecast CATX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CATX is11.82 USD with a low forecast of 4.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Perspective Therapeutics Inc (CATX)'s revenue for the last quarter?

Perspective Therapeutics Inc revenue for the last quarter amounts to 209.00K USD, decreased -43.36 % YoY.

What is Perspective Therapeutics Inc (CATX)'s earnings per share (EPS) for the last quarter?

Perspective Therapeutics Inc. EPS for the last quarter amounts to -0.35 USD, increased 66.67 % YoY.

How many employees does Perspective Therapeutics Inc (CATX). have?

Perspective Therapeutics Inc (CATX) has 138 emplpoyees as of January 30 2026.

What is Perspective Therapeutics Inc (CATX) market cap?

Today CATX has the market capitalization of 295.00M USD.

CATX Overview

CATX Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding CATX

Trading Trends

People Also Watch

Frequently Asked Questions

What is Perspective Therapeutics Inc (CATX) stock price today?

What is Perspective Therapeutics Inc (CATX)'s business?

What is the price predicton of CATX Stock?

What is Perspective Therapeutics Inc (CATX)'s revenue for the last quarter?

What is Perspective Therapeutics Inc (CATX)'s earnings per share (EPS) for the last quarter?

How many employees does Perspective Therapeutics Inc (CATX). have?

What is Perspective Therapeutics Inc (CATX) market cap?